# Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

> **NCT06973629** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Brainstorm-Cell Therapeutics** · enrollment: 200 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)
- Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** Debamestrocel - MSC-NTF (NurOwn)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06973629
- **Lead sponsor:** Brainstorm-Cell Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2028-11-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06973629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06973629, "Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06973629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*